Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsHere we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
